- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The Consolidated strategic information guidelines for viral hepatitis summarize and simplify the overall approach proposed by WHO to collect, analyse, disseminate and use strategic information on viral hepatitis at local, subnational, national and international levels.
The document describes the use of strategic information at various stages of the response in the context of strengthening broader health information systems. Strategic information can be defined as data collected at all service delivery and administrative levels to inform policy and programme decisions.
Keywords: HBV and HCV, health system, surveillance
Based on privacy, confidentiality and security principles an Assessment Tool was developed to assess in country the extent that the confidentiality and security of personal health information is protected at facility and data warehouse/repository levels and whether national guidelines exist including privacy laws. A Manual on the use of the Assessment Tool has been produced and is available below.
With scaling-up of HIV and other health services in low- and middle-income countries, an increasing amount of personally identifiable health information is being collected at health facilities and stored in data repositories at local, regional and national levels. Countries need to protect the confidentiality and security of identifiable and de-identified personal health information, and this can be accomplished in part through the existence and implementation of relevant privacy laws, policies and programmes.
These guidelines have been developed to provide updated, evidence-informed recommendations on tuberculosis (TB) infection prevention and control (IPC) in the context of the global targets of the Sustainable Development Goals (SDGs) and the World Health Organization (WHO) End TB Strategy. The notion and practice of IPC encompasses a set of broader, practical, evidence-based approaches to preventing the community from being harmed by avoidable infections, preventing health care-associated infections (HAI), implementing laboratory biosafety and reducing the spread of antimicrobial resistance (AMR).
These guidelines aim to provide evidence-based recommendations on the care and treatment of persons diagnosed with chronic HCV infection. They update the care and treatment section of the WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection issued in April 2016. The 2017 Guidelines on hepatitis B and C testing update the screening section.
These guidelines provide recommendations and good practice guidance on the optimal approach to diagnosing cryptococcal meningitis, strategies for preventing invasive cryptococcal disease through cryptococcal antigen screening and pre-emptive fluconazole therapy, treating cryptococcal meningitis with combination antifungal therapy regimens, preventing, monitoring and managing amphotericin B drug toxicity, recommendations against adjunctive therapy with systemic corticosteroids and recommendations on the timing of antiretroviral therapy (ART) initiation.
This guide supports the use of data to identify and fill gaps in services in order to improve HIV and health programmes. Following from the Consolidated Strategic Information Guidelines, high-level indicators are organized along a cascade of services which are linked to achieve outcomes. The guide supports the ways in which these cascade data are analysed and used to identify gaps and better link services.
In the past decade, national programmes and donor-funded projects have made great progress in reaching people living with HIV with life-saving treatment in countries across the globe. Measuring success of these initiatives requires strong monitoring and evaluation systems that produce high-quality data.
Efforts to ensure data quality, therefore, are not singular events occurring randomly. Rather, these processes need to become institutionalized as part of all routine data management processes.
Keywords: HIV, data, assessment, monitoring system
This Gender-Based Violence (GBV) Quality Assurance Tool offers health care providers, facilities, and program planners a straightforward way to start, strengthen or expand post-GBV health services through the use of evidence-based standards.
This document is intended to address commonly occurring situations and challenges that one faces in carrying out research with adolescents (people aged 10–19 years), the majority of whom are deemed not to have reached the recognized age of majority in their respective settings. To this end, adolescents aged 18 and 19 years are classified as adults in many settings and have the legal capacity to make autonomous decisions regarding their participation in research. In this document, the term “children” refers to people below the age of 18 years, and the term “minor adolescents” refers specifically to people aged 10–18 years.
Keywords: sexual and reproductive health, adolescent, children